FDA puts Cell Therapeutics blood cancer drug on hold after death
June 24 (Reuters) - Cell Therapeutics Inc said the U.S. Food and Drug Administration has placed a partial clinical hold on the company's experimental blood cancer drug after the death of a patient.
The patient, being treated with the drug tosedostat in combination with a chemotherapy drug, died of myocarditis, or infection of the heart muscle, the company said in a regulatory filing on Monday. ()
The company said the FDA had asked for more information and a detailed review of all cardiac events or cardiac-related investigations in patients treated with tosedostat.
Under the partial clinical hold, Cell Therapeutics cannot enroll new patients in any of the ongoing tosedostat trials until an agreement is reached with the FDA.
Cell Therapeutics shares closed at $1.22 on the Nasdaq on Friday.
- California passes 'yes-means-yes' campus sexual assault bill
- IBM launches Watson system for research, hopes for breakthroughs
- In town halls, U.S. lawmakers hear voter anger over illegal migrants |
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis |
- U.N. says 43 Golan peacekeepers seized by Syria militants, 81 trapped